Uued antikoagulandid e. NOA-d (DOAC`d) perioperatiivses situatsioonis.

Similar documents
Antiagregantravi infomaterjal arstidele

VENOOSSE TROMBEMBOOLIA RAVI AASTAL MIS ON MUUTUNUD? Katrin Nõukas TROMBOOSIKONVERENTS

Sildamine NSAID-id, antiagregandid, antikoagulandid ja nende ajutine katkestamine. Heli Kaljusaar AS ITK 2015

New Age Anticoagulants: Bleeding Considerations

Euroopa Südamerütmi Assotsiatsiooni praktilised juhised uute suukaudsete antikoagulantide kasutamise kohta kodade virvendusarütmiaga patsientidel

VARFARIIN. Hüübimise taastamine verejooksu korral või eelseisvaks kirurgiaks. Hüübivuse taastamine Kasutusel erinevad ravimirühmad:

Stolling en anesthesie. Erik Vandermeulen MD, PhD Dept. of Anesthesia

EHRA praktiline juhend uute suukaudsete antikoagulantide kasutamise kohta mittevalvulaarse kodade virvendusarütmiaga patsientidel.

to a DOAC anticoagulants (DOACs) dosing of DOACs for various indications switching from a DOAC and switching

Professional Practice Minutes December 7, 2016

Clinical issues which drug for which patient

Venoosse tromboosi profülaktika ja ravi raseduse ajal. Kai Sukles Ida-Tallinna Keskhaigla

Guidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban

The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center

Managing Hemorrhagic Complications of Non-Vitamin K Antagonist Oral Anticoagulants

Juhised arstile, kes määrab ravimit Xarelto (rivaroksabaan)

Managing Bleeding on NOACs

Anticoagulation in 2014: Using the New Agents Safely

Joost van Veen Consultant Haematologist

Novel Anticoagulants: Emerging Evidence

Management of Novel Oral Anticoagulants in Gastroenterology

Reversal of direct oral anticoagulants in the patient with GI bleeding. Marc Carrier

NOACS/DOACS*: COAGULATION TESTS

Disclosures. Overview. Have you ever. The Perioperative Management of Anticoagulants. No financial conflicts of interest to disclose

Direct Oral Anticoagulants An Update

Bridging anticoagulation definition

Challenging Anticoagulation Case Studies. Earl J. Hope, M.D. Tower Health Cardiology

The Management of Patients on Chronic Oral Anticoagulant Therapy (VKA and DOAC) who Need Elective Surgery. Alex C. Spyropoulos MD, FACP, FCCP, FRCPC

The Use of New Anticoagulants in the Elderly NOACs, DOACs,TOACs,TSOACs.

Content 1. Relevance 2. Principles 3. Manangement

Perioperative Anticoagulation Management

New Oral Anticoagulants

ADVOCATE HEALTHCARE GUIDELINE FOR ANTITHROMBOTIC REVERSAL

Antiagregantravist ja antikoagulantravist seoses müokardi revaskulariseerimisega Teele Pern II aasta kardioloogia resident

NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS

Appendix 2H - SECONDARY CARE CONVERSION GUIDELINES ORAL ANTICOAGULANTS

10 Key Things the Vascular Community Should Know about the DOACs Heather Gornik, MD, RVT, RPVI

New Oral Anticoagulants in Everyday Practice: Addressing Common Clinical Scenarios and Questions not covered by the big trials

Managing Perioperative Anticoagulation. Edie Shen MD

Update in Perioperative Anticoagulation and Antiplatelet management

Süvaveenitromboos ja kopsuarteri trombemboolia. Kai Sukles ITK 2015

Hemostasis and Thrombosis for Primary Care Providers: An Update. Andrew D. Leavitt, MD. May 21, Topic Outline. Direct Oral Anti-Coagulants DOACs

Reversal Agents for Anticoagulants Understanding the Options. Katisha Vance, MD, FACP Alabama Oncology January 28, 2017

Challenges in Coagulation

Prostate Biopsy Alerts

Faculty. DOACs and Reversal Agents: Disclosures. Considerations for Health-System Pharmacists. Learning Objectives

Update on Oral Anticoagulants. Dr. Miten R. Patel Cancer Specialists of North Florida Cell

Perioperative Management of the Anticoagulated Patient

NOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS

DOAC and NOAC are terms for a novel class of directly acting oral anticoagulant drugs including Rivaroxaban, Apixaban, Edoxaban, and Dabigatran.

Antitrombootiline ravi, laienev taustamõjur kiirabimeditsiinis. Märt Põlluveer Erakorralise meditsiini arst

REVERSAL STRATEGIES FOR ORAL ANTICOAGULATION

Coagulation BEFORE Surgery

Use of Anticoagulant Reversal Agents

DEEP VEIN THROMBOSIS (DVT): TREATMENT

The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center

Clinical Practice Committee Anticoagulation Bridging Document

Anticoagulants: Agents, Pharmacology and Reversal

Updates in Coagulation Thrombophilia testing and direct oral anticoagulants. Kevin Y. Chen, MD Hematology and Medical Oncology October 13, 2017

Post-procedure dose ok after hours. 12 hours (q 24h dosing only) assuming surgical hemostasis; second dose 24 hours after first dose.

Using an anti-xa level nomogram to adjust intravenous unfractionated heparin infusion for arrhythmia in pregnancy

Oral anti-thrombotic therapy-management in patients requiring endoscopy

on Anti-coagulants -- Is It Safe? And When to Stop?

Adult Reversal of Anticoagulation and Anti-platelet Agents for Life- Threatening Bleeding or Emergency Surgery Protocol

Anticoagulation Management Around Endoscopy: GI Perspective. Nathan Landesman, DO FACOI Flint Gastroenterology Associates October 11, 2017

Xarelto (rivaroxaban) Prescriber Guide

Emergency Management of Patients on Direct Oral Anticoagulants (DOACs)

3/25/2016. Objectives for Pharmacists. Stop the Bleeding! New Reversal Agents. Objectives for Pharmacy Technicians. Assessment Pre-test

Warfarin for Long-Term Anticoagulation. Disadvantages of Warfarin. Narrow Therapeutic Window. Warfarin vs. NOACs. Challenges Monitoring Warfarin

David Stewart, PharmD, BCPS Assistant Professor of Pharmacy Practice East Tennessee State University Bill Gatton College of Pharmacy

Patients presenting with acute stroke while on DOACs

Tim Brown, PharmD, BCACP, FASHP Director of Clinical Pharmacotherapy, Akron General Medical Center for Family Medicine Professor, Northeast Ohio

Date 29 th March 2018 Our Ref FA_Anticoag/MGPG/Mar18 Enquiries to Frances Adamson Extension Direct Line tadamson(anhs.

Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC

Oral Anticoagulation Drug Class Prior Authorization Protocol

Latest News and Clinical Applications of NOACs: What about Antidotes?

New Oral Blood Thinners and New Dilemmas: What Do We Need To Know?

Leading the Charge in Anticoagulation Reversal: Benefits, Risks, and Key Factors in Application to the Traumatically Injured Patient

Anticoagulation Reversal and Treatment Strategies in Major Bleeding: Update 2016

Dr Tina Biss Consultant Haematologist Newcastle Hospitals NHS Foundation Trust. North East RTC Annual Education Symposium 16 th October 2014

ARE THE NOVEL ORAL ANTICOAGULANTS POSING A CHALLENGE TO WARFARIN?

Update with the New Oral Anticoagulants: Today s Issues for the Front Line Pharmacist

Hemostasis. PHYSIOLOGICAL BLOOD CLOTTING IN RESPONSE TO INJURY OR LEAK no disclosures

Endoscopy in the Era of Anti- Platelet and Anti-Coagulation

Understanding Best Practices in Anticoagulation Therapy in Patients with Venous Thromboembolism. Rajat Deo, MD, MTR

Noval Oral Anticoagulants: Life Is Not As Simple as Anticipated

Antiagregandid tromboosi profülaktikaks ja raviks. H. Kaljusaar AS ITK 2014

Current Practice in Emergency Management

3/19/2012. What is the indication for anticoagulation? Has the patient previously been on warfarin? If so, what % of the time was the INR therapeutic?

Minimising and Managing bleeding with the NOACs. Dr Frances Akor Imperial College Healthcare NHS Trust

Use of Prothrombin Complex Concentrates (PCC) CONTENTS

New Anticoagulants Therapies

ALL BLEEDING STOPS EVENTUALLY! PATRICK C. CULLINAN, DO FCCM, FACOI, FACOEP SAN ANTONIO, TX

Xarelto rivaroxaban Prescriber Guide

Chances and risks of direct oral anticoagulants for VTE

Perioperative risk reduction and B-blockers. Topics. Introduction 3/26/2012

Overview of the Direct Oral Anticoagulants

NOACS/DOACS*: PERI-OPERATIVE MANAGEMENT

È possibile cambiare posologia o farmaco sulla base dei test di laboratorio?

Clinical Practice Guideline for Anticoagulation Management

Transcription:

Uued antikoagulandid e. NOA-d (DOAC`d) perioperatiivses situatsioonis. Indrek Rätsep PERH Antitrombootilise ravi perioperatiivsest käsitlusest sõltub: VeritsusRISK Kirurgiline veritsus Anesteesia valik (Spinaalhematoomi tekkerisk) Tromboosi RISK Kardio-tserebraalne trombemboolia (koronaarsündroom, insult) VTE (venoosne trombemboolia) 1

Antikoagulantravi 2 näidustust NOA-dega: Süsteemse trombemboolia ennetamine Kodade virvendusarütmia, FA korral Kopsuarteri trombemboolia ennetamine Venoosse trombembolismi (VTE) profülaktika Miks uued suukaudsed AK-d? Kui varfariinravi on raskesti teostatav. Dabigatraanil (Pradaxa), rivaroksabaanil (Xarelto), and apiksabaanil (Eliquis) on stabiilne farmakokineetiline ja dünaamiline profiil, mis võimaldab neid manustada monitooringuta. Uuringutes näidatud, et pole halvem või on isegi tõhusam kui warfariin (Marevan). Ohutusprofiil on parem kui varfariinil. Monitooring võib olla vajalik hädaolukorras kui vajalik kirurgia või on verejooks. 2

Koagulatsioonikaskaad Trombi tekkeprotsess tervikuna 3

Laboratoorsed testid. Plasma kontsentratsioone määratakse juhul kui: Verejooks Üledoos Tekkinud neerupuudulikkus Tekkinud tromboos! Erakorraline kirurgia 4

Määratakse aegasid, mida NOA mõjutab 5

Ravi katkestamine enne OP-i NB! NOA-sid ei sillata! Kuidas praktikas meelde jätta? 1-2 päeva kui normaalne neerufunktsioon (sõltuvalt kirurgiast) 2-4-6 päeva kui kreatiniini kliirens < 30 ml, pikim aeg vajalik dabigatraanil ja suure veritsusriskiga protseduuriks. 6

APTT PT & INR antixa TT Kasutatavad testid on: Normaalne TT välistab Dabi toime, kuid annuse tiitrimiseks on liiga tundlik, Ekariini aeg tulekul.. Riva ja Api hindamiseks sobib anti Xa, vajalik spets. kalibratsioon laboris 7

NOA de lõpetamine ja tromboosirisk ESA Ravijuhis Recommendations we recommend to assess creatinine clearance in patients receiving NOAs and being scheduled for surgery. 1B We suggest that NOAs should not be interrupted for skin surgery, dental and other oral procedures, gastric and colonic endoscopies (even if biopsy is scheduled, but not polypectomy), nor for most ophthalmic surggery. 8

Stop sildamiseta We recommend that for low-risk patients (e.g. Atrial fibrillationpatients with CHADS2 score 2, patientstreated for >3 months for a nonrecurrent VTE) undergoing procedures requiring normal coagulation, NOAs can be stopped 5 days before surgery. No bridging therapy is needed. 1C Stop sildamisega In patients treated with rivaroxaban, apixabanand in patients treated with dabigatranifcreatinineclearance is higher than 50 ml/min,we suggestbridging therapy for high-risk patients: (e.g. atrial fibrillationpatients with a CHADS2 score >2, patients withrecurrent VTE treated for <3 months). Day -5: last NOAdose; Day -4: no heparin; Day -3and -2: therapeutic dose oflmwh; Day -1: last injection LMWH (in the morning, i.e. 24 h before the procedure), hospitalisationand measurement of dilutedthrombin time or specific anti-fxa; Day 0: surgery. 2C 9

Intervall ravimi ja neuraksiaalse blokaadi vahel: RA ja antikoagulatsioon, EAS 2011, www.anest.ee Sisukord 1. Sissejuhatus... 4 2. Spinaalhematoom: määratlus ja tekkerisk... 5 3. Spinaalhematoomi riski vähendamine... 7 4. Fraktsioneerimata hepariin... 8 5. Madalmolekulaarne hepariin... 11 6. Teised trombiini või Xa faktori inhibiitorid... 15 7. Suukaudsed antikoagulandid (varfariin).... 17 8. Trombotsüütide agregatsiooni mõjutavad ravimid.... 21 9. Antiagregantide ja antikoagulantide kombineerimine.... 26 11. Trombolüütilise/fibrinolüütilise raviga seotud veritsused.... 27 Millal uuesti alustada? rivaroksabaan 10

Testid VEREJOOKS Toime neutraliseerimine verejooksu korral loom- ja inimuuringutes Dabigatraan 1 x päevas 4-faktori protrombiini kompleks PCC (Octaplex) doosis 25-50 U/kg omas efekti Aktiveeritud protrombiini kompleks apcc (FEIBA) doosis 40-80 U/kg veelgi parem toime. Dabigatraan 2 x päevas PCC (Octaplex) 50 U/kg ei korrigeerinud pikenenud aptt, ega TT väärtusi, ka suuremad doosid mitte! In vitro taastas need väärtused apcc (FEIBA, s.o. faktor 7+ 3PCC) Rivaroksabaan 1 x päevas Octaplex 50 U/kg normaliseeris PTT väärtuse 11

12

13

Milline võiks olla tegutsemisalgoritm Eesti haiglates.. Hinnata ravimi doosi ja patsiendi neerufunktsiooni. Dabigatraani korral dialüüs või forsseeritud diurees. Hinnata aega viimasest tarvitamiset. Manustada hüübimisfaktoreid (krüo, PCC). Manustada prokoagulatiivseid preparaate nagu apcc ja rfviia (suurem oht trombootilisteks tüsistusteks!) Tulevik Täpsem labordiagnostika Ecariini aeg Dabigatraanile Kalibreeritud antixa Rivaroksabaanile Täpsed antidoodid Monoklonaalsed antikehad Dabi-le Faktor Xa, selleks et siduda anti Xa 14